Psychedelics - Spark Newswire

2 minute read

Psychedelics Investor Acquires Firm With First-Mover Advantage In Safe Supply Narcotics Sector

Yesterday, 7:47 PM

Late Tuesday, Origin Therapeutics Holdings Inc. (CSE: ORIG), an investment issuer that has historically focused on psychedelics-industry-related companies announced it had signed a binding Letter of Intent (LOI) to acquire all of the issued and outstanding securities of Safe Supply Streaming Co., a pharmaceutical streaming and investment company in the safe supply eco

CSE:ORIG

5 minute read

Psyched: New MO, MA & NY Bills, Oregon’s Psilocybin Services, MDMA Exports, 3D Farm & More

By Lara Goldstein

Yesterday, 11:07 AM

Three More State-Level Psychedelic Bills In The Works: MO, MA And NY

PSIL

3 minute read

Women’s Footprint In Psychedelics Is Undeniable, Benzinga’s Psychedelics Advisory Council’s Six New Trailblazers

By Lara Goldstein

January 30, 1:50 PM

In its capacity as a financial news and media outlet, Benzinga has added six new members to its Psychedelics Advisory Council.

KONEF

4 minute read

Top 3 Psychedelic Storylines To Watch In 2023

By Microdose Psychedelic Insights

January 29, 12:01 PM

This article by James Hallifax was originally published on Microdose and appears here with permission.

ATAI

3 minute read

Irwin Naturals Signs LOI To Acquire Braxia Scientific Expanding Its Network Of Mental Health Clinics

By Vuk Zdinjak

January 27, 9:47 AM

Irwin Naturals Inc.

BRAXF

2 minute read

Across The Globe: Psychedelic Trials To Treat Late-Stage Cancer, Alzheimer’s Begin

By Lara Goldstein

January 26, 2:30 PM

Core One Labs' Akome Partners To Study Next-Gen Psychedelics

CLABF

3 minute read

EXCLUSIVE: Defining ‘Natural’ Psychedelics, State Regulations & Ayahuasca’s Benefits

By Lara Goldstein

January 26, 11:40 AM

(Part three of a three-part series) See previous stories: EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans

AGNPF

3 minute read

Small Pharma, Inc’s Psychedelics For Major Depression Trial Results And Q1 Earnings

By Lara Goldstein

January 25, 3:55 PM

Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF)’s proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase 2a trial for the treatment of Major Depressive Disorder (MDD).

DMTTF